216 related articles for article (PubMed ID: 10371735)
1. [Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume].
Granados Loarca EA
Arch Esp Urol; 1999 Apr; 52(3):201-8. PubMed ID: 10371735
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
[TBL] [Abstract][Full Text] [Related]
3. 5alpha-reductase inhibitors/finasteride.
Stoner E
Prostate Suppl; 1996; 6():82-7. PubMed ID: 8630236
[TBL] [Abstract][Full Text] [Related]
4. Finasteride following balloon dilatation of the prostate. A double-blind, placebo-controlled, multicenter study.
Lukkarinen O; Lehtonen T; Talja M; Lundstedt S; Tiitinen J; Taari K
Ann Chir Gynaecol; 1999; 88(4):299-303. PubMed ID: 10661828
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of benign prostatic hyperplasia with Proscar (finasteride). Results of a 10-year Scandinavian study].
Tveter KJ; Beisland HO; Andersen JT; Wolf H; Ekman P; Johansson JE; Kontturi M; Lehtonen T
Tidsskr Nor Laegeforen; 1996 Nov; 116(27):3226-30. PubMed ID: 9011975
[TBL] [Abstract][Full Text] [Related]
6. Effect of long-term administration of finasteride (MK-906), an inhibitor of 5 alpha-reductase, in patients with benign prostatic hyperplasia.
Yoshida O; Oishi K; Okada Y; Mizutani Y; Itokawa Y; Tomoyoshi T; Okada K; Komatz Y; Matsuda T; Takeuchi H
Hinyokika Kiyo; 1996 Apr; 42(4):323-31. PubMed ID: 8693970
[TBL] [Abstract][Full Text] [Related]
7. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002).
Vela-Navarrete R; Gonzalez-Enguita C; Garcia-Cardoso JV; Manzarbeitia F; Sarasa-Corral JL; Granizo JJ
BJU Int; 2005 Nov; 96(7):1045-8. PubMed ID: 16225526
[TBL] [Abstract][Full Text] [Related]
8. [Finanseride in symtomatic benign prostatic hyeprtrophy. A 2-year placebo-controlled study].
Andersen JT; Wolf H; Ekman P; Beisland HO; Johansson JE; Kontturi M; Lehtonen T; Tveter K
Ugeskr Laeger; 1996 Sep; 158(36):5030-5. PubMed ID: 8928243
[TBL] [Abstract][Full Text] [Related]
9. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.
Stoner E
Arch Intern Med; 1994 Jan; 154(1):83-8. PubMed ID: 7505563
[TBL] [Abstract][Full Text] [Related]
10. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
McDonald H; Hux M; Brisson M; Bernard L; Nickel JC
Can J Urol; 2004 Aug; 11(4):2327-40. PubMed ID: 15380054
[TBL] [Abstract][Full Text] [Related]
11. [Contribution of the PCPT trial to finasteride treatment of micturition disorders due to benign prostatic hyperplasia].
de la Taille A
Prog Urol; 2008 Apr; 18 Suppl 3():S53-7. PubMed ID: 18455085
[TBL] [Abstract][Full Text] [Related]
12. [New prospective therapy for benign prostatic hyperplasia with finasteride].
Miano L; Manieri C; Paradiso Galatioto G; Vicentini C
Riv Eur Sci Med Farmacol; 1993; 15(2):111-9. PubMed ID: 7513437
[TBL] [Abstract][Full Text] [Related]
13. [Flutamide, an alternative for patients with benign prostatic hyperplasia (BPH) that cannot be treated with surgery].
Granados EA
Arch Esp Urol; 1998 Sep; 51(7):675-9. PubMed ID: 9807893
[TBL] [Abstract][Full Text] [Related]
14. Early diagnosis of prostate cancer in finasteride treated BPH patients.
Tarle M; Kraus O; Trnski D; Reljic A; Ruzic B; Katusic J; Spajic B; Kusic Z
Anticancer Res; 2003; 23(1B):693-6. PubMed ID: 12680169
[TBL] [Abstract][Full Text] [Related]
15. Effect of finasteride treatment on suburethral prostatic microvessel density in patients with hematuria related to benign prostate hyperplasia.
Memis A; Ozden C; Ozdal OL; Guzel O; Han O; Seckin S
Urol Int; 2008; 80(2):177-80. PubMed ID: 18362489
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
Suzuki H; Yano M; Awa Y; Nakatsu H; Egoshi K; Mikami K; Ota S; Okano T; Hamano S; Ohki T; Furuya Y; Ichikawa T
Int J Urol; 2006 Sep; 13(9):1202-6. PubMed ID: 16984553
[TBL] [Abstract][Full Text] [Related]
17. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
18. [Finasteride (Proscar) for benign prostatic hypertrophy].
Matzkin H; Chen J; Braf Z
Harefuah; 1993 Dec; 125(12):453-6, 496. PubMed ID: 7509305
[TBL] [Abstract][Full Text] [Related]
19. Finasteride in the treatment of benign prostatic hyperplasia.
Ekman P; Andersen JT; Wolf H
Acta Urol Belg; 1996 Mar; 64(1):IX-XII. PubMed ID: 8659328
[TBL] [Abstract][Full Text] [Related]
20. [Long-term results of proscar (finasteride, MSD) treatment of patients with benign prostatic hyperplasia].
Tkachuk VN; Al'-Shukri SKh; Kornienko VI; Kuz'min IV
Urol Nefrol (Mosk); 1998; (4):37-9. PubMed ID: 9727320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
